… the HRs of the BRAF mutation for recurrence. In conclusion, the BRAF mutation does not
increase the … Differences in the geographical region or tumor stage should be considered when …

… of the BRAF mutation in our cohort of papillary thyroid cancer patients was 56%. BRAF
mutation-positive tumours were associated with a more locally advanced disease, and these …

… most thyroid nodules are benign. The main clinical relevance of thyroid nodules is the possibility
of thyroid carcinoma, … are finally proved to be papillary thyroid carcinoma (PTC), whose …

… At present, researchers are working on determining the role of BRAF mutation in patients
from a low-risk group and its correlations with others molecular events. Currently, …

… Our dataset included an unselected cohort of papillary thyroid carcinoma (PTC) patients
who … BRAF mutation is an independent predictor of papillary thyroid carcinoma long-term …

… To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological
risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the …

… The BRAF V600E mutation is a recognised molecular marker in papillary thyroid cancer (PTC), …
The aim of this study was to evaluate BRAF mutation as a prognostic biomarker in PTC. …

… with the BRAF mutation and patients with wild-type BRAF and found that the BRAF mutation
was … In the current prognosis evaluation system of thyroid cancer, the patient's age is a …

… mutation OR BRAF mutation” AND “clinical characteristics OR prognostic factor OR risk factor”
AND “papillary thyroid carcinoma OR PTC OR papillary thyroid microcarcinoma OR PTMC”…

… BRAF mutation and papillary thyroid carcinoma (PTC), and further explore the relationship
between the systemic inflammation response index (SIRI) and BRAF mutation … BRAF mutation …